Summary
Bristol Myers Squibb (BMY) reported its third-quarter 2023 financial results, demonstrating resilience in its key therapeutic areas despite ongoing challenges. The company's performance was shaped by a mix of strong execution in certain product lines and the continued impact of patent expirations on older revenue streams. Investors should note the strategic focus on a diversified portfolio and pipeline development as key drivers for future growth, with management emphasizing progress in clinical trials and regulatory submissions. The company is navigating a complex market, balancing innovation with the need to manage the lifecycle of its established products.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $10.97B |
| Cost of Revenue | $2.51B |
| Gross Profit | $8.46B |
| R&D Expenses | $2.24B |
| SG&A Expenses | $2.00B |
| Operating Expenses | $8.83B |
| Interest Expense | $280.00M |
| Net Income | $1.93B |
| EPS (Basic) | $0.94 |
| EPS (Diluted) | $0.93 |
| Shares Outstanding (Basic) | 2.06B |
| Shares Outstanding (Diluted) | 2.06B |
Key Highlights
- 1Third-quarter 2023 revenue showed a slight decrease compared to the prior year, reflecting the expected impact of estimative product exclusivity losses and an ongoing strategic shift.
- 2The company continues to invest heavily in Research and Development (R&D), a critical component for fueling its long-term growth pipeline with innovative therapies.
- 3Gross margin remained robust, indicating effective cost management and the pricing power of BMY's key in-line and new product portfolio.
- 4Operating expenses, including significant R&D and SG&A, reflect ongoing strategic investments and business development activities.
- 5The company's cash flow from operations remained strong, supporting its debt obligations, dividend payments, and strategic investments.
- 6BMY is actively managing its product portfolio, with a focus on newer, higher-growth assets to offset declines in mature products.